| Generic Name | ||
|---|---|---|
| IND | BMS 536924 | |
| Brand Name (US) | ||
| Manufacturer | Bristol-Myers Squibb | |
| Drug Type | Tyrosine Kinase Inhibitor | |
| Delivery | Oral | |
| Approval Status | Phase 1 | |
| Indications | ||
| Overall Strategy | GIST cell based | |
| Strategy | Block related tumor signal paths | |
| Drug Category | IGF1R inhibitor | |
This is a IGF1R inhibitor in early development. IGF1R is overexpressed in 2/3 of wild-type GISTs and almost all pediatric GISTs. 
Patients with wild-type GIST and pediatric GIST may be good candidates for a trial with inhibitors of IGF1R.
| Links | |
| Trials of this drug | |
| Trial results |